Avacta is developing its Affimer technology for use in therapeutic and diagnostic/reagent applications. The potential of the Affimer technology lies in its formatting capabilities, particularly in the creation of bispecific and TMAC Affimer drug conjugates. Its lead therapeutic asset (AVA004) is a programmed death-ligand 1 (PD-L1)-targeting Affimer for which the company expects to submit an investigational new drug (IND) application in Q420. AVA004 will serve as the first clinical validation of ....
13 Jun 2019
Avacta Group - Affimer - potential best-in-class antibody mimetic
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Avacta Group - Affimer - potential best-in-class antibody mimetic
Avacta Group PLC (AVCT:LON) | 45.2 0 (-0.1%) | Mkt Cap: 162.5m
- Published:
13 Jun 2019 -
Author:
Dr Daniel Wilkinson - Pages:
Avacta is developing its Affimer technology for use in therapeutic and diagnostic/reagent applications. The potential of the Affimer technology lies in its formatting capabilities, particularly in the creation of bispecific and TMAC Affimer drug conjugates. Its lead therapeutic asset (AVA004) is a programmed death-ligand 1 (PD-L1)-targeting Affimer for which the company expects to submit an investigational new drug (IND) application in Q420. AVA004 will serve as the first clinical validation of ....